Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CMA1 | P23946 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13096 | 0.97 | IDO1 (0.58) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL1657653 | 0.95 | IDO1 (0.56) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL8993257 | 0.91 | LTA4H (0.65) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL6157954 | 0.91 | LTA4H (0.54) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL2996706 | 0.91 | MAOB (0.59) | IDO1CA12CA1CA2CA7 | |
| (Chloromethyl)Benzene SCHEMBL28005139 | 0.89 | LTA4H (0.69) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL28148603 | 0.87 | IDO1 (0.48) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL5505882 | 0.85 | APP (0.67) | IDO1AGXTALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28784521 | 0.85 | APP (0.67) | IDO1AGXTALDH1A1MAPTSMN1; SMN2 | |
| Bicarbonate SCHEMBL28421098 | 0.83 | CA1 (0.52) | IDO1CA1CA2ALDH1A1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100548950-C | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2009-10-14 | — | — | CN | claimed |
| CN-1759084-A | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2006-04-12 | — | — | CN | claimed |
| US-20260042736-A1 | COMPOSITIONS AND METHODS FOR MAKING SCYTONEMIN AND ITS ANALOGS AND DERIVATIVES | Board of Regents of Nevada System of Higher Education on behalf of the University of Nevada Reno (US) | 2026-02-12 | — | — | US | disclosed |
| CN-116102407-B | Method for preparing gastrodia elata extract 2, 4-bis (4-hydroxybenzyl) phenol | 北京化工大学 | 2024-07-23 | — | — | CN | disclosed |
| CN-116102407-A | Method for preparing gastrodia elata extract 2, 4-bis (4-hydroxybenzyl) phenol | 北京化工大学 | 2023-05-12 | — | — | CN | disclosed |
| CN-112047919-B | Ticagrelor intermediate and preparation method thereof | 常州制药厂有限公司 | 2021-06-18 | — | — | CN | disclosed |
| CN-112047919-A | Ticagrelor intermediate and preparation method thereof | 常州制药厂有限公司 | 2020-12-08 | — | — | CN | disclosed |
| EP-2399577-A1 | Use of N-containing spirocompounds for the enhancement of cognitive function | Adolor Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| US-8022060-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2011-09-08 | — | — | US | disclosed |
| US-20100029614-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-7230139-B2 | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents | GEMIN X BIOTECHNOLOGIES (CA) | 2007-06-12 | — | — | US | disclosed |
| US-7217844-B2 | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents | GEMIN X BIOTECHNOLOGIES (CA) | 2007-05-15 | — | — | US | disclosed |
| US-20060270695-A1 | Spirocyclic heterocyclic derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006105442-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| CN-1759084-A | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2006-04-12 | — | — | CN | disclosed |
| US-20050070540-A1 | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2005-03-31 | — | — | US | disclosed |
| US-20050032802-A1 | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents | GEMIN X BIOTECHNOLOGIES INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005003103-A2 | 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | WO | disclosed |
| US-5260451-A | Enzyme inhibitors | MERCKLE GMBH (DE) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | IDO1 1463/4885CA12 2102/4885CA1 1362/4885 |
| US-20260042736-A1 | COMPOSITIONS AND METHODS FOR MAKING SCYTONEMIN AND ITS ANALOGS AND DERIVATIVES | TDO2, SCO2, TPH1 | IDO1 8/4885CA12 2255/4885CA1 2967/4885 |
| US-20050070540-A1 | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents | CYP51A1, ERG28, BAD | IDO1 467/4885CA12 896/4885CA1 1596/4885 |
| US-20100029614-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | IDO1 1463/4885CA12 2102/4885CA1 1362/4885 |
| US-20060270695-A1 | Spirocyclic heterocyclic derivatives and methods of their use | OPRK1, OPRD1, OPRL1 | IDO1 1463/4885CA12 2102/4885CA1 1362/4885 |
| US-20050032802-A1 | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents | CYP51A1, ERG28, BAD | IDO1 467/4885CA12 896/4885CA1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.